C12N 2760/14011
Filoviridae
C12N2760/14011 (Filoviridae) appears on 190 US grants and 330 published applications in this corpus.
Search patents in C12N- Granted patents
- 190
- Published applications
- 330
- Assignees
- 188
- Inventors
- 514
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 2 |
| 2003 | 4 | 8 |
| 2004 | 1 | 6 |
| 2005 | 2 | 8 |
| 2006 | 3 | 10 |
| 2007 | 3 | 4 |
| 2008 | 1 | 2 |
| 2009 | 5 | 4 |
| 2010 | 4 | 13 |
| 2011 | 4 | 11 |
| 2012 | 8 | 10 |
| 2013 | 4 | 7 |
| 2014 | 5 | 10 |
| 2015 | 9 | 12 |
| 2016 | 8 | 20 |
| 2017 | 7 | 28 |
| 2018 | 10 | 24 |
| 2019 | 13 | 15 |
| 2020 | 20 | 28 |
| 2021 | 17 | 20 |
| 2022 | 19 | 24 |
| 2023 | 9 | 18 |
| 2024 | 12 | 25 |
| 2025 | 16 | 12 |
| 2026 | 5 | 9 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/14111EbolavirusIndexing code176
- C12N 2760/14211MarburgvirusIndexing code50
- C12N 2760/14022New viral proteins or individual genes, new structural or functional aspects ofIndexing code15
- C12N 2760/14034Use of virus or viral component as vaccineIndexing code12
- C12N 2760/14071Demonstrated in vivo effectIndexing code2
- C12N 2760/14033Use of viral protein as therapeutic agent other than vaccineIndexing code1
- C12N 2760/14051Methods of production or purification of viral materialIndexing code1
- C12N 2760/14021Viruses as suchIndexing code0
All 14 subgroupsShow fewer
- C12N 2760/14023Virus like particles [vlp]Indexing code0
- C12N 2760/14031Uses of virus other than therapeutic or vaccineIndexing code0
- C12N 2760/14032Use of virus as therapeutic agent, other than vaccineIndexing code0
- C12N 2760/14041Use of virus, viral particle or viral elements as a vectorIndexing code0
- C12N 2760/14061Methods of inactivation or attenuationIndexing code0
- C12N 2760/14088For redistributionIndexing code0
Recent patents
- Antiviral structurally-stabilized Ebolavirus peptides and uses thereof6 Oct 2026US 12,753,208 B2Dana-Farber Cancer Institute, Inc.
- Compositions and methods for membrane protein structure determination12 May 2026US 12,624,092 B2The Regents of the University of Michigan
- Vaccines and uses thereof to induce an immune response to SARS-CoV217 Mar 2026US 12,577,589 B2GeoVax, Inc.
- Recombinant viruses, insect cells and their uses in viral detection and vaccination24 Feb 2026US 12,560,607 B2Academia Sinica
- Chimeric filovirus vaccines10 Feb 2026US 12,545,709 B2Katholieke Universiteit Leuven
- Purification of viruses and viral like particles8 Oct 2026US 2026/0308616 A1Interius Biotherapeutics, Inc.
- Vaccines and methods6 Aug 2026US 2026/0224686 A1Cambridge Enterprise Limited
- Immunogenic ebolavirus fusion proteins and related methods23 Jul 2026US 2026/0207728 A1CZ Biohub SF, LLC
- Engineered virus-like-particles for targeted capture of membrane proteins16 Jul 2026US 2026/0200991 A1
- Systems and methods for the production of human polyclonal antibodies11 Jun 2026US 2026/0159574 A1Sab, LLC
Most cited
By later US patents
- Adenovirus vector with multiple expression cassettes110US 6,544,780 B1GenPhar, Inc. · 2003
- Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use102US 7,247,472 B2The Trustees of the University of Pennsylavania · 2007
- Compositions and methods for silencing ebola virus gene expression98US 9,187,748 B22015
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions75US 10,188,748 B2CureVac AG · 2019
- Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses63US 7,491,508 B2The Trustees of the University of Pennsylvania · 2009